FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice

Author:

Yakala Gopala K.1,Cabrera-Fuentes Hector A.23456,Crespo-Avilan Gustavo E.23,Rattanasopa Chutima12,Burlacu Alexandrina7,George Benjamin L.3,Anand Kaviya1,Mayan David Castaño1,Corlianò Maria1,Hernández-Reséndiz Sauri23,Wu Zihao1,Schwerk Anne M.K.8,Tan Amberlyn L.J.1,Trigueros-Motos Laia1,Chèvre Raphael1,Chua Tricia1,Kleemann Robert89,Liehn Elisa A.31011,Hausenloy Derek J.23121314,Ghosh Sujoy23,Singaraja Roshni R.1

Affiliation:

1. From the Translational Laboratories in Genetic Medicine, A*STAR Institute, and Yong Loo Lin School of Medicine, National University of Singapore (G.K.Y., C.R., K.A., D.C.M., M.C., Z.W., A.L.J.T., L.T.-M., R.C., T.C., R.R.S.)

2. Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore (H.A.C.-F., G.E.C.-A., C.R., S.H.-R., D.J.H., S.G.)

3. National Heart Research Institute, National Heart Centre Singapore (H.A.C.-F., G.E.C.-A., B.L.G., S.H.-R., E.A.L., D.J.H., S.G.)

4. Institute of Biochemistry, Medical School, Justus-Liebig-University, Giessen, Germany (H.A.C.-F.)

5. Department of Microbiology, Kazan Federal University, Russian Federation (H.A.C.-F.)

6. Tecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Centro de Biotecnologia-FEMSA, Nuevo Leon, México (H.A.C.-F.)

7. Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest, Romania (A.B.)

8. Department of Metabolic Health Research, The Netherlands Organization for Applied Scientific Research (TNO), Leiden (A.M.K.S., R.K.)

9. Department of Vascular Surgery, Leiden University Medical Center, the Netherlands (R.K.)

10. Institute of Molecular Cardiovascular Research, RWTH, Aachen, Germany (E.A.L.)

11. Human Genetic Laboratory, University of Medicine, Craiova, Romania (E.A.L.)

12. Yong Loo Lin School of Medicine, National University Singapore (D.J.H.)

13. The Hatter Cardiovascular Institute, University College London, United Kingdom (D.J.H.)

14. The National Institute of Health Research, University College London Hospitals Biomedical Research Centre, United Kingdom (D.J.H.)

Abstract

Objective— Atherosclerotic coronary artery disease is the leading cause of death worldwide, and current treatment options are insufficient. Using systems-level network cluster analyses on a large coronary artery disease case-control cohort, we previously identified PCSK3 (proprotein convertase subtilisin/kexin family member 3; FURIN ) as a member of several coronary artery disease–associated pathways. Thus, our objective is to determine the role of FURIN in atherosclerosis. Approach and Results— In vitro, FURIN inhibitor treatment resulted in reduced monocyte migration and reduced macrophage and vascular endothelial cell inflammatory and cytokine gene expression. In vivo, administration of an irreversible inhibitor of FURIN, α-1-PDX (α1-antitrypsin Portland), to hyperlipidemic Ldlr −/− mice resulted in lower atherosclerotic lesion area and a specific reduction in severe lesions. Significantly lower lesional macrophage and collagen area, as well as systemic inflammatory markers, were observed. MMP2 (matrix metallopeptidase 2), an effector of endothelial function and atherosclerotic lesion progression, and a FURIN substrate was significantly reduced in the aorta of inhibitor-treated mice. To determine FURIN’s role in vascular endothelial function, we administered α-1-PDX to Apoe −/− mice harboring a wire injury in the common carotid artery. We observed significantly decreased carotid intimal thickness and lower plaque cellularity, smooth muscle cell, macrophage, and inflammatory marker content, suggesting protection against vascular remodeling. Overexpression of FURIN in this model resulted in a significant 67% increase in intimal plaque thickness, confirming that FURIN levels directly correlate with atherosclerosis. Conclusions— We show that systemic inhibition of FURIN in mice decreases vascular remodeling and atherosclerosis. FURIN-mediated modulation of MMP2 activity may contribute to the atheroprotection observed in these mice.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3